Search - tctmd.com

Displaying 101 - 120 of 195

Sort: Relevancy | Date

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

August 31, 2019

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

News Daily News

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

July 23, 2019

TCTMD’s Top 10 Most Popular Stories for June 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

June 28, 2019

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

News Features

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

June 25, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

News Conference News HRS 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

May 17, 2019

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

News Daily News

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

April 08, 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

March 25, 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

News Conference News EHRA 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

March 21, 2019

For Acute A-fib, Wait-and-See Approach May Spare Many Patients From Cardioversion

News Conference News EHRA 2019

For Acute A-fib, Wait-and-See Approach May Spare Many Patients From Cardioversion

March 18, 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

News Conference News EHRA 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

March 17, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

News Daily News

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

March 08, 2019

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

News Daily News

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

February 25, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

News Conference News ISC 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

February 07, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.